

Supporting Information

Identification of Proteins Adducted by Lipid Peroxidation Products in Plasma and Modifications of Apolipoprotein A1 with a Novel Biotinylated Probe

Matthew E. Szapacs, Hye-Young H. Kim, Ned A. Porter and Daniel C. Liebler

Departments of Biochemistry and Chemistry, Vanderbilt University, Nashville, Tennessee

37232-0146.

Table S1 and S2

Figure S1 and S2

Table S1. ω-end electrophile adducts found in ApoA1 from plasma supplemented with PLPBSO

| sequences | positions | mass shifts | | | |
|----------------|------------------|-------------|-----|----|----|
| | | 126 | 112 | 98 | 84 |
| VK*DLATVYVDVLK | K12 | x | | | x |
| DLEEVK*AK | K94 | x | x | | x |
| AK*VQPYLDDFQK | K96 | x | | x | x |
| K*WQEEMELYR | K107 | x | | x | x |
| QK*VEPLR | K118 | | x | | |
| QK*LH*ELQEK | K133 or /H135 | x | | | |
| LH*ELQEK | H135 | x | | | |
| AH*VDALR | H155 | | x | x | x |
| TH*LAPYSDELRL | H162 | | x | x | x |
| LAEYH*AK | H193 | x | | x | |
| AK*PALEDLR | K208 | x | | x | x |

Mass shifts: 126: nonanal, 112: octanal, 98: heptanal, 84: hexanal
x: found

Table S2. Complete list of proteins identified from plasma following supplementation and oxidation in the presence of PLPBSO, affinity purification and base hydrolysis.

| Protein name | Accession # | Average % Coverage |
|--|----------------|--------------------|
| 163 kDa protein | IPI00465313.2 | 19.60% |
| ALB protein | IPI00216773.4 | 58.60% |
| Alpha-1-antitrypsin precursor | IPI00553177.1 | 26.90% |
| Apolipoprotein A-I precursor | IPI000218541.1 | 68.30% |
| Apolipoprotein A-II precursor | IPI00021854.1 | 49.00% |
| Apolipoprotein A-IV precursor | IPI00304273.1 | 34.40% |
| Apolipoprotein B-100 precursor | IPI00022229.1 | 5.00% |
| Apolipoprotein D precursor | IPI00006662.1 | 18.50% |
| Apolipoprotein E precursor | IPI00021842.1 | 30.60% |
| Apolipoprotein C-III precursor | IPI00021857.1 | 19.20% |
| Beta-globin gene from a thalassemia patient | IPI00382950.1 | 15.50% |
| Complement C3 precursor | IPI00164623.4 | 24.80% |
| Complement C4-A precursor | IPI00032258.4 | 8.60% |
| Factor VII active site mutant immunoconjugate | IPI00382606.1 | 5.30% |
| Fibrinogen beta chain precursor | IPI00298497.3 | 18.00% |
| Ig gamma-2 chain C region | IPI00399007 | 6.30% |
| Ig mu heavy chain disease protein | IPI00385264.1 | 13.50% |
| Inter-alpha-trypsin inhibitor heavy chain H1 precursor | IPI00292530.1 | 9.80% |
| Inter-alpha-trypsin inhibitor heavy chain H2 precursor | IPI00305461 | 10.20% |
| Serum amyloid A-4 protein precursor | IPI00019399.1 | 24.60% |
| Serum paraoxonase/arylesterase 1 | IPI00218732.2 | 17.20% |

Figure S1. Total ion current LC-MS trace of peptides from a tryptic digest of oxidized plasma supplemented with PLPBSO (A) and oxidized, unsupplemented plasma (B). Plasma was supplemented with PLPBSO and then incubated with the free radical initiator AIPH as described under Experimental Procedures. After oxidation, biotinylated (PLPBSO-adducted) plasma proteins were captured on streptavidin-agarose, digested and analyzed by LC-MS. Very little non-specific binding was detected in the control sample (B).






Figure S2. MS-MS spectra of ApoA1 adducts formed with PLPBSO oxidation products or HNE.

a. KODA (M+210) adduct of ApoA1 peptide QLNL*K⁴⁵LLDNWDSVTSTFSK




b. HODA (M+228) non-reduced Michael adduct of ApoA1 peptide

A*H¹⁵⁵VDALRTHLAPYSDEL R




c. 7-oxooctanoic acid imine adduct (M + 128) of ApoA1 peptide LEAL*K¹⁸²ENGGAR




d. HODA (M+156) 9-oxononanoic acid imine adduct of ApoA1 peptide


LAEYHA*K¹⁹⁵ATEHLSTLSEK




e. HNE (M+158) reduced Michael adduct of ApoA1 peptide V*K¹²DLATVYVDVLK




f. HNE (M+158) reduced Michael adduct of ApoA1 peptide DLATVYVDVL*K²³DSGR




g. HNE (M+158) reduced Michael adduct of ApoA1 peptide DLEEV*K⁹⁴AK




h. HNE (M+158) reduced Michael adduct of ApoA1 peptide A*K⁹⁶VQPYLDDFQK




i. HNE (M+158) reduced Michael adduct of ApoA1 peptide *K¹⁰⁷WQEEMELYR




j. HNE (M+158) reduced Michael adduct of ApoA1 peptide L*H¹³⁵ELQEK




k. HNE (M+158) reduced Michael adduct of ApoA1 peptide A*H¹⁵⁵VDALR




1. HNE (M+158) reduced Michael adduct of ApoA1 peptide LAEY*H¹⁹³AK



m. HNE (M+158) reduced Michael adduct of ApoA1 peptide ATE*H¹⁹⁹LSTLSEK



n. HNE (M+158) reduced Michael adduct of ApoA1 peptide A*K²⁰⁸PALEDLR



o. HNE (M+158) reduced Michael adduct of ApoA1 peptide VSFLSALEEYT* K^{238} -K

